Several medications are currently approved by the FDA to treat Alzheimer’s disease, though they work best in early to moderate stages and do not reverse the disease. The most established options belong to two categories: cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and memantine, an NMDA receptor antagonist.
These medications aim to slow cognitive decline by protecting remaining brain cells and boosting communication between neurons, though individual responses vary widely—some people notice meaningful slowing of memory loss, while others see minimal benefit. For example, a person diagnosed with early-stage Alzheimer’s might start on donepezil (commonly prescribed under the brand name Aricept), often with the expectation that it may help preserve independence and cognitive function for a period of months to a few years. A neurologist or geriatrician will monitor response over weeks and months, adjusting doses or switching medications if side effects prove intolerable or if cognition continues declining.
Table of Contents
- What Are the Most Commonly Prescribed Alzheimer’s Medications?
- How Do Cholinesterase Inhibitors Work and What Are Their Limits?
- Understanding Memantine and Combination Therapy
- Managing Side Effects and Medication Adherence
- Important Warnings About What These Medications Cannot Do
- Recent Medications and Emerging Options
- Drug Interactions and Monitoring Requirements
What Are the Most Commonly Prescribed Alzheimer’s Medications?
The older established medications—cholinesterase inhibitors and memantine—remain the backbone of Alzheimer’s treatment. Donepezil is typically the first medication tried and can be used across all disease stages. Rivastigmine and galantamine are also cholinesterase inhibitors approved for mild to moderate Alzheimer’s. Memantine works through a different mechanism and is approved for moderate to severe disease, though doctors sometimes prescribe it alongside cholinesterase inhibitors for a combination approach. Each drug comes with a different side effect profile, which influences choice.
Donepezil, for instance, can cause nausea, diarrhea, and sleep disturbances—side effects that sometimes emerge gradually as the dose increases over weeks. Rivastigmine carries similar risks and requires slow dose escalation. Galantamine may cause dizziness or appetite loss. Memantine is generally better tolerated but can produce dizziness, confusion, or headache in some patients. The goal is finding a medication that slows decline without creating quality-of-life problems that outweigh the cognitive benefit.
How Do Cholinesterase Inhibitors Work and What Are Their Limits?
Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, a neurotransmitter critical for memory and learning. By preserving available acetylcholine in the brain, these drugs may help neurons communicate more effectively for a time. However, this mechanism only works when there are still enough healthy neurons to benefit from the preserved acetylcholine—in advanced Alzheimer’s, when neurodegeneration is severe, the benefit tends to disappear. A significant limitation is that cholinesterase inhibitors do not stop the underlying disease process.
Plaques and tangles—the hallmarks of Alzheimer’s—continue to accumulate in the brain despite medication. Patients and families must understand that the goal is to slow decline, not halt or reverse it. Some people on these medications experience a stable period of several months to a couple of years before decline resumes. Others see no noticeable change. There is no reliable way to predict who will benefit before starting treatment, which means decisions often involve trial and adjustment.
Understanding Memantine and Combination Therapy
Memantine works differently from cholinesterase inhibitors; it blocks NMDA receptors to reduce the damaging effects of excess glutamate, another neurotransmitter. This drug is most commonly prescribed for moderate to severe Alzheimer’s, stages where cholinesterase inhibitors have become less effective. Some doctors combine memantine with a cholinesterase inhibitor to target multiple pathways simultaneously.
Combination therapy is based on the reasoning that attacking the disease through different mechanisms might produce better results than a single drug alone. However, the evidence for meaningful superiority of combination therapy over single-agent treatment remains limited. Adding a second medication also increases the risk of side effects and drug interactions, particularly in older adults who take multiple medications for heart disease, diabetes, or other conditions. For example, someone on warfarin for atrial fibrillation might experience increased bleeding risk if memantine interacts with other medications in their regimen.
Managing Side Effects and Medication Adherence
Tolerability directly affects whether someone continues a medication long enough to potentially benefit. Cholinesterase inhibitors require slow dose escalation, often increasing every few weeks, to allow the body to adjust and reduce initial nausea or gastrointestinal upset. If side effects remain severe even at low doses, switching to a different drug in the same class is an option—some people tolerate one cholinesterase inhibitor better than another.
Taking these medications with food, timing doses to avoid peak nausea, and maintaining hydration can help manage gastrointestinal side effects. However, if someone develops persistent vomiting, severe diarrhea, or other intolerable effects, stopping the medication may be the right choice despite the theoretical benefit. Dementia progression is unpredictable—some people naturally experience slow decline regardless of medication, while others decline rapidly. Balancing the small chance of slowing that decline against definite discomfort is a highly individual decision that families and doctors make together.
Important Warnings About What These Medications Cannot Do
A critical reality is that no current Alzheimer’s medication reverses cognitive loss or stops disease progression permanently. At best, these drugs may slow decline for a time. Marketing materials or well-meaning family members sometimes suggest that starting medication early will “prevent” Alzheimer’s in someone with mild cognitive impairment—this is not supported by evidence. These medications treat symptomatic Alzheimer’s, not preclinical disease. Another limitation involves heart and respiratory effects.
Some cholinesterase inhibitors can slow heart rate (cause bradycardia) or increase salivation and respiratory secretions. People with existing cardiac conduction problems or respiratory disease need close monitoring. Memantine can occasionally cause respiratory depression. Additionally, these medications should be used cautiously or avoided entirely in people with certain conditions like acute myocardial infarction, unstable angina, or obstructive airway disease. A complete medical history and careful review of all medications is essential before starting any Alzheimer’s drug.
Recent Medications and Emerging Options
Recent additions to the approved medication list represent a shift in Alzheimer’s treatment, though data on long-term effectiveness in real-world populations remains limited. These newer agents target different mechanisms than the older medications and may work better for some patients, but availability, cost, and administration requirements create practical barriers for many people.
Discussing options with a neurologist or geriatrician requires updated information about which drugs your insurance covers, which specialist clinics in your area can administer them, and realistic timelines for seeing any benefit. Early-stage diagnosis offers the best window for trying newer medications, though individual circumstances vary widely.
Drug Interactions and Monitoring Requirements
Anyone starting an Alzheimer’s medication should ensure their primary care doctor, cardiologist, and pharmacist all know about it. These drugs interact with numerous common prescriptions—blood thinners, heart medications, pain relievers, and psychiatric drugs can all produce problematic combinations. A specific example: someone on both donepezil and a beta-blocker might experience an additive slowing of heart rate that requires dose adjustment or discontinuation.
Regular monitoring through follow-up appointments, blood work when indicated, and careful observation of new symptoms is essential. Doctors typically check liver and kidney function periodically, since these organs metabolize many medications. If new symptoms appear—dizziness, falls, urinary problems, or worsening confusion—the medication itself may be the culprit, not disease progression. Family members and caregivers play a crucial role in reporting these changes, as people with cognitive decline may not remember or recognize subtle new problems.
- —
